Personalized approaches to help people quit smoking in regular doctor's visits
A multilevel intervention to personalize and improve tobacco treatment in primary care
This project aims to help more people successfully quit smoking by tailoring cessation medications to their individual genetic makeup and other biological factors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11109450 on NIH RePORTER |
What this research studies
Many people find it hard to quit smoking, and current methods don't always work well because doctors don't always prescribe the right medication, or patients don't use it consistently. This project explores a new way to personalize smoking cessation by using information from your genes and how your body processes nicotine. By matching you with the most effective and safest medication for your unique biology, we hope to make quitting easier and more successful. This personalized approach could also encourage doctors to prescribe these tailored treatments more often and motivate patients to stick with their medication.
Who could benefit from this research
Good fit: Ideal candidates for future studies related to this research would be individuals who smoke and are interested in quitting, particularly those who have found standard cessation methods ineffective.
Not a fit: Patients who do not smoke or are not interested in quitting would not directly benefit from this specific research opportunity.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized ways for individuals to quit smoking, potentially reducing cancer risk and improving overall health.
How similar studies have performed: Emerging evidence, including a recent Cochrane review and the researchers' own work, suggests that genetic markers and nicotine metabolism are associated with a person's ability to quit smoking and respond to cessation medication.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Chen, Li-Shiun — Washington University
- Study coordinator: Chen, Li-Shiun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.